Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Code | Description |
---|---|
J9359 | Injection, loncastuximab tesirine-lpyl, 0.075 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 6 | 6 | 1 | — | 1 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Follicular lymphoma | D008224 | — | C82 | 2 | 4 | — | — | — | 6 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 3 | 3 | — | — | — | 5 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 1 | — | — | — | 4 |
B-cell lymphoma | D016393 | — | — | 2 | 2 | — | — | — | 4 |
Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 2 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 1 | — | — | — | 2 |
Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Burkitt lymphoma | D002051 | — | C83.7 | 2 | — | — | — | — | 2 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
Drug common name | Loncastuximab |
INN | loncastuximab |
Description | Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1879918-31-6 |
RxCUI | — |
ChEMBL ID | CHEMBL4297238 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16222 |
UNII ID | NYM5HO7I39 (ChemIDplus, GSRS) |